Eikon Therapeutics Doses First Patient In TeLurRide-008, A Phase 2/3 Registrational Study Of EIK1001 In Combination With Pembrolizumab And Histology-Appropriate Chemotherapy For Stage 4 Non-Small Cell Lung Cancer

Loading news article.

Eikon Therapeutics Doses First Patient In TeLurRide-008, A Phase 2/3 Registrational Study Of EIK1001 In Combination With Pembrolizumab And Histology-Appropriate Chemotherapy For Stage 4 Non-Small Cell Lung Cancer | WAPE

Eikon Therapeutics Doses First Patient In TeLurRide-008, A Phase 2/3 Registrational Study Of EIK1001 In Combination With Pembrolizumab And Histology-Appropriate Chemotherapy For Stage 4 Non-Small Cell Lung Cancer

Article summary

Related companies

Comments —